Pandemic Influenza Preparedness and Response 2016-2021

The Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response established this Master IDIQ for Medical Countermeasures (MCMs) for Pandemic Influenza Preparedness and Response on August 22, 2016, with ordering authority that closed on August 21, 2021. This vehicle is no longer active; all 40 task orders have been awarded and fully obligated at $177.4 million combined potential value. New orders cannot be placed against this contract.

The vehicle contracted vaccine development, manufacturing, clinical studies, and stockpile maintenance activities across influenza strains including H5N1, H7N9, and pandemic preparedness candidates. Task orders funded bulk lot manufacture, formulation and fill operations, storage and stability testing of antigen and finished containers, manufacture of seed lots and reference standards, and phase I clinical studies for vaccine candidates. Pricing structures were predominantly firm fixed price, with one cost-sharing arrangement for clinical studies.

Three primes dominated the awards. Sanofi Vaccines US Inc. received 18 orders totaling $77.5 million combined potential value; Glaxosmithkline, LLC received 12 orders totaling $62.4 million; and Protein Sciences Corp received 9 orders totaling $35.7 million. A single order of $1.8 million went to Medimmune LLC. These three firms captured 99% of the vehicle's value. All task orders were unrestricted procurements with no set-asides. All 40 orders funded the awarding agency directly; no other agencies placed orders against the vehicle.

Ordering activity peaked in 2017 and 2019 at 11 orders each year, declining to 6 orders in 2018 and 2020, with a final order in February 2022. Individual task-order values ranged from under $50,000 to approximately $40.6 million, with the largest single order being for H7N9 bulk lots at $40,642,758. Average task-order ceiling was approximately $4.4 million. Task-order performance periods ranged from a few months to multi-year efforts, with multiple orders extending performance through 2023 and 2024 despite the August 2021 ordering cutoff.

Medical Countermeasures (MCMs) for Pandemic Influenza Preparedness and Response